Zentek Ltd. (NASDAQ:ZTEK) Short Interest Update

Key Points

• Zentek Ltd. experienced a 27.5% decline in short interest in August, with the total short interest falling from 119,800 shares to 86,800 shares.
• The company's shares have seen significant fluctuations, with a 1-year low of $0.50 and a high of $1.84, currently trading at $0.95.
• For the latest quarter, Zentek reported a negative net margin of 981.17% and revenue of $0.04 million.

Zentek Ltd. (NASDAQ:ZTEK - Get Free Report) was the target of a significant drop in short interest in August. As of August 31st, there was short interest totaling 86,800 shares, a drop of 27.5% from the August 15th total of 119,800 shares. Currently, 0.1% of the shares of the stock are sold short. Based on an average daily volume of 281,000 shares, the days-to-cover ratio is currently 0.3 days. Based on an average daily volume of 281,000 shares, the days-to-cover ratio is currently 0.3 days. Currently, 0.1% of the shares of the stock are sold short.

Zentek Trading Down 6.2%

Shares of ZTEK opened at $0.95 on Tuesday. Zentek has a 1-year low of $0.50 and a 1-year high of $1.84. The company has a debt-to-equity ratio of 0.12, a current ratio of 1.62 and a quick ratio of 1.30. The firm's 50 day simple moving average is $0.86 and its 200 day simple moving average is $1.13. The company has a market capitalization of $99.21 million, a P/E ratio of -18.95 and a beta of 0.59.

Zentek (NASDAQ:ZTEK - Get Free Report) last issued its quarterly earnings results on Thursday, August 14th. The company reported ($0.01) EPS for the quarter. Zentek had a negative net margin of 981.17% and a negative return on equity of 55.41%. The business had revenue of $0.04 million for the quarter.

Zentek Company Profile

Zentek Ltd., together with its subsidiaries, engages in the research and development of graphene and related nanomaterials in Canada. The company develops graphene-based antimicrobial coating under the ZenGUARD brand, surgical masks, HVAC filters, personal protective equipment, rapid detection point of care diagnostics tests, and pharmaceutical products based on graphene-based compounds.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.